Last update 08 May 2025

OCUL101

Overview

Basic Info

Drug Type
Bispecific antibody
Synonyms
Target
C5 x VEGFR
Action
inhibitors, antagonists
Mechanism
C5 inhibitors(Complement C5 inhibitors), VEGFR antagonists(Vascular endothelial growth factor receptor antagonists)
Therapeutic Areas
Cardiovascular DiseasesCongenital DisordersEndocrinology and Metabolic Disease+ [1]
Active Indication
Diabetic macular oedemaGeographic AtrophyWet age-related macular degeneration
Inactive Indication-
Originator Organization
Shenzhen Okejian Biomedical Technology Co., Ltd.
Active Organization
Shenzhen Okejian Biomedical Technology Co., Ltd.
Inactive Organization-
License Organization-
Drug Highest PhasePhase 1/2
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with OCUL101
CTR20250853
/ RecruitingPhase 1/2
一项评估玻璃体内注射 OCUL101 在新生血管性年龄相关性黄斑变性、糖尿病性黄斑水肿和继发于年龄相关性黄斑变性的地图样萎缩患者中安全性、耐受性、药代动力学、药效学和初步疗效的剂量递增、剂量扩展的 I/II 期研究
[Translation] A Phase I/II Dose-Escalation, Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Intravitreal OCUL101 in Patients with Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema, and Geographic Atrophy Secondary to Age-Related Macular Degeneration
100 Clinical Results associated with OCUL101
Login to view more data
100 Translational Medicine associated with OCUL101
Login to view more data
100 Patents (Medical) associated with OCUL101
Login to view more data
100 Deals associated with OCUL101
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Diabetic macular oedemaPhase 2
China
Shenzhen Okejian Biomedical Technology Co., Ltd.
01 Apr 2025
Geographic AtrophyPhase 2
China
Shenzhen Okejian Biomedical Technology Co., Ltd.
01 Apr 2025
Wet age-related macular degenerationPhase 2
China
Shenzhen Okejian Biomedical Technology Co., Ltd.
01 Apr 2025
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
view full example data
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free